BNC Korea Co., Ltd. (KOSDAQ:256840)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,110.00
-60.00 (-1.44%)
Apr 28, 2026, 3:30 PM KST
-2.61%
Market Cap 281.10B
Revenue (ttm) 95.90B
Net Income (ttm) 2.84B
Shares Out 68.39M
EPS (ttm) 42.00
PE Ratio 97.86
Forward PE n/a
Dividend 70.00 (1.70%)
Ex-Dividend Date Dec 29, 2025
Volume 285,987
Average Volume 463,358
Open 4,165.00
Previous Close 4,170.00
Day's Range 4,095.00 - 4,165.00
52-Week Range 3,645.00 - 6,310.00
Beta 0.70
RSI 54.41
Earnings Date Mar 27, 2026

About BNC Korea

BNC Korea Co., Ltd. engages in the research and development, production, and sale of biomaterials for medicines in South Korea. The company offers BIENOX Inj. for temporary improvement of moderate to severe glabellar wrinkles associated with corrugator muscle and/or procerus muscle activity in adults; Juvegel for temporary improvement of moderate to severe nasolabial folds in adults; and Collapleo Plus, a collagen-based material for the supplementation of damaged or deficient ligaments, tendons, muscles, and fascia. It also provides HA fillers ... [Read more]

Sector Healthcare
Founded 2007
Employees 250
Stock Exchange KOSDAQ
Ticker Symbol 256840
Full Company Profile

Financial Performance

In 2025, BNC Korea's revenue was 95.90 billion, an increase of 7.47% compared to the previous year's 89.23 billion. Earnings were 2.84 billion, a decrease of -78.68%.

Financial Statements

News

There is no news available yet.